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Abstract
Background: Association between rectal or colon cancer risk and serine hydroxymethyltransferase 1 (SHMT1)
C1420T or methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms was assessed. The serum total
homocysteine (HCY), marker of folate metabolism was also investigated.
Methods: The SHMT1 and MTHFR genotypes were determined by real-time PCR and PCR-RFLP, respectively in 476
patients with rectal, 479 patients with colon cancer and in 461 and 478, respective controls matched for age and
sex. Homocysteine levels were determined by HPLC kit. The association between polymorphisms and cancer risk
was evaluated by logistic regression analysis adjusted for age, sex and body mass index. The population
stratification bias was also estimated.
Results: There was no association of genotypes or diplotypes with colon cancer. The rectal cancer risk was
significantly lower for SHMT1 TT (OR = 0.57, 95% confidence interval (CI) 0.36-0.89) and higher for MTHFR CT
genotypes (OR = 1.4, 95%CI 1.06-1.84). A gene-dosage effect was observed for SHMT1 with progressively
decreasing risk with increasing number of T allele (p = 0.014). The stratified analysis according to age and sex
revealed that the association is mainly present in the younger (< 60 years) or male subgroup. As expected from
genotype analysis, the SHMT1 T allele/MTHFR CC diplotype was associated with reduced rectal cancer risk (OR 0.56,
95%CI 0.42-0.77 vs all other diplotypes together). The above results are unlikely to suffer from population
stratification bias. In controls HCY was influenced by SHMT1 polymorphism, while in patients it was affected only
by Dukes’ stage. In patients with Dukes’ stage C or D HCY can be considered as a tumor marker only in case of
SHMT1 1420CC genotypes.
Conclusions: A protective effect of SHMT1 1420T allele or SHMT1 1420 T allele/MTHFR 677 CC diplotype against
rectal but not colon cancer risk was demonstrated. The presence of SHMT1 1420 T allele significantly increases the
HCY levels in controls but not in patients. Homocysteine could be considered as a tumor marker in SHMT1 1420
wild-type (CC) CRC patients in Dukes’ stage C and D. Further studies need to clarify why SHMT1 and MTHFR
polymorphisms are associated only with rectal and not colon cancer risk.
Background
Colorectal cancer (CRC) is the second leading cause of
cancer morbidity in Hungary both in male and female
populations, and is one of the most frequent cause of
cancer-related deaths. The mean age of the patients at
the diagnosis of CRC is about 60 years and yearly about
9,000 new cases occur including approximately 2,800
newly diagnosed rectal cancer cases. Numerous results
have been accumulated suggesting the role of folate and
folate-related enzyme polymorphisms in the etiology of
CRC. Low folate intake or low bioavailability of circulat-
ing folate, key components of one-carbon metabolism,
have been related to increased risk of CRC [1]. The
results, however, are still not conclusive. In a recent
report an opposite influence of folate on different stages
of the adenoma-carcinoma sequence was documented
[2]. On the other hand, there are studies providing evi-
dence for the significance of genetic polymorphisms of
folate-cycle enzymes (e.g. methylenetetrahydrofolate
reductase (MTHFR)) in colorectal carcinogenesis [3].
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cing CRC susceptibility is also inconsistent [4,5]. In a
meta-analysis of 25 studies Hubner et al.r e p o r t e dt h a t
MTHFR 677TT genotype is associated with a significant,
but moderately reduced risk of CRC [6]. Another less
widely studied enzyme of folate/one-carbon metabolism,
the cytosolic serine hydroxymethyltransferase (SHMT1),
has a frequent but functionally less characterized Leu- >
Phe polymorphism (SNP variant C1420T). This poly-
morphism was associated with significantly reduced risk
of acute lymphocytic leukemia [7] and malignant lym-
phoma [8], but not colorectal adenoma [9]. However, in
aC R Cs t u d yn oe v i d e n c eo fg e n ei n f l u e n c eo nt h er i s k
or association of this polymorphism with folate or
homocysteine (HCY) levels were found [10]. The modi-
fying effect of SHMT1 C1420T polymorphism on CRC
risk remained undecided [11,12].
Rectal and colon cancer differ in their histology, diag-
nosis, sensitivity to radiotherapy and prognosis as well
[13]. The treatment of rectal cancer usually includes
preoperative radiotherapy, while colon cancer is non-
radiosensitive. Both types of cancer have similar and
also different risk factors [14,15]. Low folate and/or
excessive alcohol intake are risk factors for both disease,
but the physical activity have different effect on their
risk [14]. In a large prospective US cohort body mass
index (BMI) was related to increased risk of colon, but
not rectal cancer [16]. There are few studies investigat-
ing the genetic risk factors separately in rectal and colon
cancer, showing net differences between rectal and
colon cancer [17-19]. The inconsistent results of the
previous studies examining the polymorphisms in CRC
may arise from the fact that dissimilar proportions of
rectal and colon cancer cases were included in the
investigations. Based on this information ascertained
above the separate investigation of rectal and colon can-
cer cases is reasonable.
The SHMT1 is a vitamin B6 dependent enzyme that
catalyzes the reversible conversion of serine and tetrahy-
drofolate (THF) to glycine and 5,10-methylenetetrahy-
drofolate (5,10-MTHF), a reaction which provides one-
carbon units for S-adenosylmethionine (SAM), and for
purine and pyrimidine synthesis.
Methylenetetrahydrofolate reductase irreversibly con-
verts 5,10-MTHF to 5-methyltetrahydrofolate (5-
methylTHF) using vitamin B2 as a cofactor. 5-
methylTHF is the most stable and abundant form of
folate metabolites, which in turn is the methyl donor in
the conversion of HCY into methionine. Decrease in
MTHFR reductase activity could lead to impaired HCY
catabolism. There are two common functional SNPs on
the MTHFR gene, which are in close linkage: the C677T
and the A1298C substitutions. The C677T polymorph-
ism on the exon 4 results in an Ala- > Val substitution
at codon 222. Compared to the MTHFR 677C homozy-
gotes the TT and CT genotypes have 70% and 30%
lower enzyme activity, respectively. The 677T allele has
been associated with elevated plasma HCY levels [20].
In contrast, the exact functional consequence of the
A1298C polymorphism is not well defined, and because
of the linkage the extent of its independent contribution
remains inconclusive [21,22].
Homocysteine is a sulphur-containing amino acid,
produced mainly by S-adenosyl-methionine mediated
methylation reactions. It is well-known that the total
serum homocysteine (HCY) level among others is influ-
enced by gender (higher in males), age (increasing with
ageing), BMI (increased in obese individuals) and renal
function (increased in renal impairment) [23-25]. More-
over, its accumulation in the serum is related to a num-
ber of disease conditions: vascular disease, cancer,
neural tube defect, etc [26]. HCY reflects the combined
pool of free, albumin bound, reduced and oxidized
forms of HCY in the blood. Remethylation of homocys-
teine by methionine synthase, a vitamin B12 dependent
enzyme, is the major metabolic pathway. The HCY level
is inversely associated with the folate level and was sug-
gested to be a risk factor of cancers [27,28]. Moreover a
s t u d ys u g g e s t e dt h er o l eo fH C Ya sat u m o rm a r k e ro f
CRC [27]. This finding led to the exclusion of HCY
from our analysis of cancer risk to avoid an eventual
bias.
The aim of our study was to separately analyze the
risk of rectal and colon cancer in association with
SHMT1 C1420T and MTHFR C677T polymorphisms.
The effect of the studied polymorphisms on the serum
total HCY levels was also investigated.
Methods
Study population
For this case-control study 955 patients with colorectal
adenocarcinoma were included. Cases of colon and rectal
cancers were 476 and 479, respectively. The 461 and 478
sex and age matched healthy individuals recruited all
across Hungary were considered as controls. Consecutive
series of patients from all regions of the country diag-
nosed with rectal or colon tumors (Dukes’ s t a g eA ,B ,C
and D) between 2001-2007 and who underwent surgery,
radiotherapy and/or chemotherapy at the National Insti-
tute of Oncology (NIO) were included. This institute is
one of the largest radiotherapy centre in Hungary there-
fore it treats higher number of rectal cancer patients than
the average number treated elsewhere in Hungary. Out
of the 24 patients with rectosigmoid lesion only 12, who
ever received radiotherapy, were enrolled in the rectal
cancer group. Patients with previous history of cancer or
with synchronous cancer were not included in the study.
All patients with hyperhomocysteinemia (HCY > 35 μM)
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cases with proven or suspected familial adenomatous
polyposis or hereditary nonpolyposis colorectal cancer
were also excluded. The control population comprised
healthy blood donors, healthcare workers or non-cancer
patients from different regions of the country. The body
mass index (BMI) was recorded both for controls and
patients.
Written informed consent was obtained from all
patients and controls before enrolment or sample with-
drawal. The study was approved by the Ethics Commit-
tee of NIO.
Preparation of the samples
Blood samples from patients and controls were collected
after overnight fasting into EDTA (15%) containing
tubes. Peripheral blood mononuclear cells (PBMC) were
isolated from the whole blood by Ficoll gradient. DNA
from PBMC was extracted according to the manufac-
turer’s instructions using Master Pure TM Genomic
DNA Purification Kit (Epicentre Technologies, Madison,
WI, USA). The aliquots of blood plasma were frozen
within 10 minutes after blood sampling and stored at
-84°C for HCY determination according to the instruc-
tions of the HCY kit (Immundiagnostik AG, Bensheim,
Germany).
Genotyping and serum total homocysteine (HCY)
determination
The MTHFR C677T (rs1801133) genotypes were deter-
m i n e db yP C R - R F L Pi nc o n f o r m i t yw i t ht h em e t h o d
described by Frosst et al. [29]. About 10% of the sam-
ples were re-examined by an investigator who had not
attended the previous collection of data. There were no
discrepancies in the results.
To determine the SHMT1 C1420T polymorphism
(rs1979277) an allele discrimination method using
fluorogenic 3’-minor groove binding (MGB) probes
described by Skibola et al. was adapted [7]. The real-
time PCR was performed in Rotorgene 2000 real-time
cycler (Corbette Research, Mortlake, Australia). About
10% of the samples were parallel genotyped by real-time
PCR and PCR-RFLP method using Eam1104I restriction
enzyme (Fermentas Inc., Hanover, MD, USA). The dis-
crepancy between the methods was below 1%.
The HCY level was determined by HPLC technique
applying the HCY kit (Immundiagnostik AG, Bensheim,
Germany). The interassay variability (overall coefficient
of variation, %) of quality control samples was 4.4%. In
patients the HCY levels were determined prior to surgi-
cal intervention and/or (radio)chemotherapy in fasting
state.
During the above processes the investigators were
blinded from sample categories.
Statistical analysis
The means and proportions between cases and controls
were compared by t test and c
2 test for goodness-of-fit,
respectively, except for HCY where Mann-Whitney U
test was used. The difference in the distribution of
diplotypes was analysed by pooling the groups with var-
iant allele(s). Beside sex, the median age of 60 years was
used as threshold for stratification. The association
between polymorphisms and cancer risk was evaluated
by logistic regression analysis adjusted for age, sex and
BMI. In case of stratified analysis according to sex, age
or BMI the adjustment was made for age and BMI, sex
and BMI or age and sex, respectively. The results are
given as odds ratio (OR) and 95% confidence interval
(95% CI). Trends in the OR (gene dosage effect) were
calculated by assigning ordinal values to the genotypes.
The Hardy-Weinberg equilibrium (HWE) was tested
using the Haploview 4.1 software (Daly Lab at the Broad
Institute, Cambridge, MA, USA).
The assumable potential impacts of population stratifi-
cation bias in the studied population were estimated
with the formulas of Lee and Wang [30]. The used for-
mula is: U = (GB)
1/2 [(GB)
1/2+1]
2[(GB)
1/2 +G]
-1[(GB)
1/2
+B]
-1,w h e r eG=A HAL
-1(1-AL)(1-AH)
-1 and B =
DHDL
-1;A H, L - highest and lowest allele frequency; DH,
L - highest and lowest disease rate. The effective OR
should be higher than the calculated U in order to have
a result, which cannot be explained away by population
stratification bias alone.
The SHMT1 C1420T genotype frequencies of Eur-
opean countries found in dbSNP [31], the MTHFR
C677T genotype frequencies in Hungary presented in 12
independent publications and the colon and rectal can-
cer incidences in Europe [32] and in Hungary (National
Cancer Registry for 2001-2007, I. Gaudi, personal com-
munication) were used.
The age, sex, BMI and Dukes’ stage adjusted HCY
mean values in different geno- and diplotype groups
were compared by Kruskal-Wallis ANOVA and Krus-
kal-Wallis Z post hoc test. The same analysis for differ-
ent Dukes’ stages was applied for HCY mean levels
adjusted for age, sex and BMI. The linear trend was also
tested for different Dukes’ stages. The patients with
Dukes’ stage A, because of their low number, were
included in the group with stage B.
All statistical tests were performed with NCSS soft-
ware (Hintze, J. 2001. NCSS and PASS. Number
Cruncher Statistical System, Kaysville, UT, http://www.
ncss.com). A level of 5% or if the 95% CI did not
include unity was considered significant.
Results
Selected characteristics and the genotype distributions
of patients and controls are summarized in Table 1.
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patients (mean ± SE: 20.8 ± 0.30; p < 0.0001 and 19.1
± 0.27; p < 0.0001 for colon and rectal cancer, respec-
tively) than in controls (17.9 ± 0.32 and 17.7 ± 0.30)
(Table 1). The distribution of SHMT1 C1420T and
MTHFR C677T genotypes in controls and cases was in
conformity with the HWE (SHMT1: controls p = 0.131
and colon cancer p = 0.843; controls p = 0.167 and
rectal cancer p = 0.973; MTHFR: controls p = 0.074
and colon cancer p = 0.063; controls p = 0.126 and
rectal cancer p = 0.403).
The univariate comparison of raw genotype distribu-
tions of cases and controls revealed significant difference
only in case of rectal cancer for both SHMT1 C1420T
and MTHFR C677T polymorphisms. An opposite
distribution shift from variant homozygotes toward wild
type and from wild type to hetorozygotes was present in
case of SHMT1 and MTHFR, respectively, hence the
SHMT1 CT+TT/MTHFR CC diplotypes were signifi-
cantly underrepresented among cases with rectal cancer
(Table 1). The distribution of unpooled diplotype groups
is provided in the Additional file 1.
No association was observed in colon cancer for
SHMT1 and MTHFR CT or TT genotypes compared
w i t ht h eC Cg e n o t y p e( T a b l e2 ) .I nc o n t r a s tw i t hc o l o n
cancer, the adjusted risk ratio for rectal cancer was sig-
nificantly lower for SHMT1 TT and higher for MTHFR
CT genotypes. A gene-dosage effect was observed only
for SHMT1 with the progressively decreasing risk ratio
with increasing number of T allele (p = 0.014).
Table 1 Selected characteristics and genotype frequencies of SHMT1 C1420T and MTHFR C677T polymorphisms of
patients with colon cancer, rectal cancer and that of the respective controls
Parameters Control Colon cancer p Control Rectal cancer p
n = 461 n = 476 n = 478 n = 479
n (%) n (%) n (%) n (%)
Age (years)
mean ± SD 59.2 ± 12.4 59.5 ± 11.9 0.733 58.9 ± 11.1 58.9 ± 10.5 0.938
< 60 230 (50) 226 (47) 0.300 246 (51) 238 (50) 0.437
≥60 231 (50) 250 (53) 232 (49) 241 (50)
Sex
male 218 (47) 227 (48) 0.863 304 (64) 302 (63) 0.803
female 243 (53) 249 (52) 174 (36) 177 (37)
BMI
mean ± SD 26.2 ± 3.9 26.2 ± 4.0 1.000 26.5 ± 3.5 26.4 ± 4.3 0.882
Dukes’ stage
A 3 (1) 3 (1)
B 107 (22) 102 (21)
C 181 (38) 220 (46)
D 185 (39) 154 (32)
SHMT1 C1420T
CC 220 (48) 228 (48) 0.360 220 (46) 249 (52) 0.002
CT 186 (40) 201 (42) 198 (41) 192 (40)
TT 55 (12) 47 (10) 60 (13) 38 (8)
CT+TT 241 (52) 248 (52) 0.939 258 (54) 230 (48) 0.009
MTHFR C677T*
CC 216 (47) 208 (44) 0.396 226 (47) 190 (40) 0.002
CT 186 (40) 196 (42) 194 (41) 231 (48)
TT 59 (13) 68 (14) 58 (12) 58 (12)
CT+TT 245 (53) 264 (56) 0.230 252 (53) 289 (60) 0.001
SHMT1 /MTHFR
CC/CC 89 (19) 93 (20) 0.160 91 (19) 103 (22) < 0.001
CC/CT+TT 131 (29) 132 (28) 129 (27) 146 (30)
CT+TT/CC 127 (28) 115 (24) 135 (28) 87 (18)
CT+TT/CT+TT 114 (24) 132 (28) 123 (26) 143 (30)
Serum total homocysteine
mean ± SD 17.9 ± 6.9 20.8 ± 6.5 < 0.0001 17.7 ± 6.6 19.1 ± 5.9 < 0.0001
* genotyping failed in 4 colon cancer patients
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revealed that the association of rectal cancer with these
polymorphisms was present only in younger (< 60 year)
or male subgroups (Table 2). Interestingly, in case of
colon cancer an opposite effect of the presence of
MTHFR variant allele was seen for younger (OR > 1)
and older patients (OR < 1), however, the association
was significant only in the former case. In the stratified
analysis according to the BMI (< 25 vs ≥25) there were
non-significant differences only (data not shown).
Analyzing the association of cancer risk with diplo-
types (Table 3) it was observed that the presence of
SHMT1 T allele decreased the risk of rectal cancer only
in case of wild type MTHFR. As had been expected
from the results of genotype analysis the risk reducing
effect of SHMT1 T allele was completely abolished
when the MTHFR T allele was present. The ORs for all
diplotypes is provided in the Additional file 1.
As the distribution of SHMT1 C1420T genotypes are
not available for the Hungarian population the European
genotype frequencies and rectal cancer incidences were
used instead to gauge any potential population stratifica-
tion bias. The SHMT1 1420 CC+CT frequency in Eur-
ope ranges from 0.833 to 0.913 [31], the rectal cancer
incidence ranges from approximately 9 to 37 per 100
000 inhabitants in different countries in Europe [32].
Using the formula of Lee and Wang it was found that
t h eu p p e rb o u n df o rt h eb i a si s1 . 2 9 ,w h i c hi sl e s st h a n
Table 2 Overall, sex- and age-specific risk of colon and
rectal cancer according to SHMT1 C1420T and MTHFR
C677T polymorphisms
Colon cancer p Rectal cancer p
OR* (95% CI) p
† OR* (95% CI) p
†
SHMT11420
CC 1.00 (reference) 0.611 1.00 (reference) 0.014
CT 1.07 (0.81-1.41) 0.62 0.86 (0.66-1.13) 0.27
TT 0.86 (0.56-1.33) 0.49 0.57 (0.36-0.89) 0.013
CT+TT 1.02 (0.79-1.32) 0.90 0.80 (0.62-1.03) 0.08
MTHFR 677
CC 1.00 (reference) 0.338 1.00 (reference) 0.083
CT 1.08 (0.81-1.42) 0.61 1.40 (1.06-1.84) 0.016
TT 1.19 (0.80-1.78) 0.39 1.14 (0.75-1.73) 0.53
CT+TT 1.11 (0.87-1.44) 0.43 1.35 (1.04-1.74) 0.024
Males
SHMT11420
CC 1.00 (reference) 0.334 1.00 (reference) 0.015
CT 0.93 (0.63-1.39) 0.73 0.92 (0.65-1.29) 0.63
TT 0.75 (0.40-1.39) 0.36 0.42 (0.23-0.75) 0.003
CT+TT 0.89 (0.61-1.30) 0.54 0.80 (0.58-1.10) 0.16
MTHFR 677
CC 1.00 (reference) 0.121 1.00 (reference) 0.494
CT 1.36 (0.91-2.05) 0.14 1.45 (1.03-2.05) 0.034
TT 1.42 (0.80-2.50) 0.23 0.89 (0.52-1.51) 0.67
CT+TT 1.37 (0.94-2.00) 0.10 1.29 (0.94-1.79) 0.12
Females
SHMT11420
CC 1.00 (reference) 0.824 1.00 (reference) 0.390
CT 1.22 (0.83-1.80) 0.31 0.77 (0.49-1.22) 0.27
TT 0.94 (0.50-1.74) 0.83 0.97 (0.47-2.01) 0.93
CT+TT 1.13 (0.79-1.62) 0.50 0.80 (0.52-1.22) 0.29
MTHFR 677
CC 1.00 (reference) 0.863 1.00 (reference) 0.052
CT 0.87 (0.59-1.28) 0.48 1.39 (0.88-2.19) 0.16
TT 1.07 (0.60-1.90) 0.82 1.81 (0.91-3.60) 0.09
CT+TT 0.93 (0.65-1.33) 0.68 1.45 (0.94-2.23) 0.09
Age < 60 years
SHMT11420
CC 1.00 (reference) 0.485 1.00 (reference) 0.002
CT 1.22 (0.82-1.82) 0.33 0.81 (0.55-1.19) 0.29
TT 0.67 (0.37-1.23) 0.19 0.32 (0.16-0.61) 0.0006
CT+TT 1.08 (0.74-1.57) 0.69 0.69 (0.48-0.99) 0.044
MTHFR 677
CC 1.00 (reference) 0.047 1.00 (reference) 0.112
CT 1.72 (1.15-2.59) 0.008 1.97 (1.33-2.92) 0.0007
TT 1.37 (0.77-2.44) 0.29 0.98 (0.54-1.76) 0.94
CT+TT 1.65 (1.14-2.39) 0.008 1.67 (1.16-2.40) 0.005
Age ≥ 60 years
SHMT11420
CC 1.00 (reference) 0.943 1.00 (reference) 0.763
CT 0.91 (0.62-1.34) 0.64 0.90 (0.61-1.32) 0.58
TT 1.13 (0.59-2.18) 0.71 1.04 (0.54-1.98) 0.91
CT+TT 0.92 (0.64-1.33) 0.67 0.92 (0.64-1.31) 0.63
Table 3 Colon and rectal cancer risk based on SHMT1
1420/MTHFR 677 diplotypes
Diplotypes Colon cancer Rectal cancer
SHMT1/
MTHFR
case/
control
OR* (95%
CI)
case/
control
OR* (95% CI)
CC/CC 93/89 1.00
(reference)
103/91 1.00
(reference)
CC/CT+TT 132/131 0.95 (0.65-
1.39)
146/129 0.99 (0.69-
1.44)
CT+TT/CC 115/127 0.87 (0.59-
1.27)
87/135 0.57 (0.39-
0.84)
†
CT+TT/CT+TT 132/114 1.10 (0.75-
1.62)
143/123 1.02 (0.71-
1.48)
* adjusted for age, sex and BMI;
† different from reference (p = 0.005) or CT
+TT/CT+TT (p = 0.002)
Table 2: Overall, sex- and age-specific risk of colon and
rectal cancer according to SHMT1 C1420T and MTHFR
C677T polymorphisms (Continued)
MTHFR 677
CC 1.00 (reference) 0.489 1.00 (reference) 0.432
CT 0.70 (0.47-1.03) 0.07 1.03 (0.70-1.52) 0.89
TT 0.99 (0.56-1.73) 0.96 1.33 (0.73-2.42) 0.35
CT+TT 0.75 (0.52-1.08) 0.13 1.08 (0.74-1.56) 0.70
* adjusted for BMI, sex and age for overall risk, BMI and age for sex-specific
risk, BMI and sex for age-specific risk; † test of gene-dosage effect
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study for carriers of SHMT1 1420C allele in Hungary.
In the case of MTHFR C677T, we have found 12 inde-
pendent publications for the Hungarian population, thus
the range of CT+TT frequencies were in the range of
0.412-0.7. The rectal cancer incidence in Hungary
ranges from approximately 32 to 38 per 100,000 indivi-
duals, thus the upper bound for the bias is 1.05, which
is less than 1.38 found for Hungarian MTHFR 677T
allele carriers.
In order to investigate the effect of SHMT1 C1420T
and MTHFR C677T polymorphisms the age, sex and
BMI adjusted mean HCY levels in different diplotypes
were compared in controls and patients. The HCY levels
of patients were also adjusted for Dukes’ stage, because
the mean HCY levels were significantly higher in
advanced stages of the disease (Table 4). In controls the
presence of SHMT1 variant allele resulted in signifi-
cantly higher HCY levels while this effect could not be
observed in patients. The MTHFR Ta l l e l eh a dn o
unequivocal effect on HCY levels. The adjusted mean
HCY levels of all diplotypes are presented in the Addi-
tional file 1.
Discussion
In our study both investigated polymorphisms, SHMT1
C1420T and MTHFR C677T, exert influence on the risk
of rectal but not on that of colon cancer. Previous stu-
dies underline the capacity of SHMT1 C1420T poly-
morphism being directly related to cancer susceptibility.
Skibola et al. found risk reduction for the SHMT1
1420TT genotype in adult acute lymphocytic leukemia
[7]. The same result was found by Hishida et al.i n
malignant lymphomas [8]. Recently, it was observed that
in a North Chinese population there was a reduced risk
of esophageal squamous cell carcinoma and gastric car-
dia adenocarcinoma in the case of SHMT1 1420CT het-
erozygotes compared to C homozygotes [33]. In the
above mentioned studies the risk reduction influenced
b yt h ep r e s e n c eo fSHMT1 1420T allele was in accor-
dance with our findings regarding rectal cancer. The
variant SHMT1 enzyme may result in decreased produc-
tion of 5,10-MTHF and accumulation of tetrahydrofo-
late, although the exact biological effect of this
phenomenon or the complete mechanism leading to
carcinogenesis is not yet known.
In a case-control study van den Donk et al. could not
demonstrate association between colorectal adenoma
risk and SHMT1 C1420T polymorphism. Unfortunately,
the authors performed a stratified analysis according to
sex and not to the adenoma localization [9].
Chen et al. could not prove any risk-reducing effect of
the variant type SHMT1 C1420T polymorphism in case
of CRC [10]. In his study only male cases and male hos-
pital-based controls were used from Caucasian-Ameri-
can populations, but the rectal and colon cancer
patients were not separately analyzed, thus the risk
modifying effect of the SHMT1 C1420T polymorphism
might be obscured. Guerreiro et al. found an increased
risk of CRC in case of SHMT1 1420 C allele, although
the strength of their observation is limited by the small
number of variant homozygotes (n = 9) and moreover,
the rectal and colon cancer patients were analyzed
together [11]. Steck et al. found a borderline statistically
significant decreased risk of colon cancer in whites, but
not African Americans, with the SHMT 1420TT
Table 4 Mean serum total homocysteine levels according to Dukes’ stage and SHMT1 1420/MTHFR 677 diplotypes in
colon and rectal cancer patients and respective controls
Mean serum total homocysteine* (95% CI) [μM]
Dukes’ stage Control Colon cancer Control Rectal cancer
17.9 (17.3-18.5) 17.7 (17.1-18.3)
A, B 19.4 (16.9-21.8) 18.3 (16.9-19.6)
C 20.8 (19.1-22.5)° 19.1 (17.9-20.2)°
D 21.6 (20.7-22.6)° 20.4 (19.6-21.3)°
p
† = 0.031 p
† = 0.036
for trend p = 0.059 for trend p = 0.053
SHMT1/MTHFR Control Colon cancer** Control Rectal cancer**
CC/CC 15.6 (14.2-17.0) 20.7 (18.9-22.5)° 15.9 (14.6-17.2) 19.4 (18.0-20.8)°
CC/CT+TT 16.2 (15.1-17.4) 21.5 (20.1-22.8)° 15.3 (14.4-16.1) 21.0 (19.7-22.2)°
CT+TT/CC 19.1 (17.9-20.2)
# 22.8 (21.0-24.5)° 19.3 (18.1-20.5)
# 19.6 (17.9-21.4)
CT+TT/CT+TT 20.3 (19.1-21.6)
# 21.4 (19.8-23.0) 19.8 (18.6-21.0)
# 20.8 (19.7-21.9)
p
† < 0.0001 p
† = 0.155 p
† < 0.0001 p
† = 0.221
* adjusted for age, sex and BMI; ** also adjusted for Dukes’ stage;
† Kruskal-Wallis one-way ANOVA;
# different from CC/CC or CC/CT+TT, Z-value test p < 0.05;° different from control, Mann-Whitney U-test p < 0.01
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Page 6 of 10genotype as compared to the CC genotype. High folate
intake reduced the risk of colon cancer in all genotypes.
In this study the control group for whites deviated
strongly from HWE (p = 0.0042) [12].
The presence of the MTHFR 677T allele represented a
higher rectal, but not colon cancer risk compared to CC
homozygotes. The relationship of MTHFR C677T poly-
morphism and CRC risk based on the results of pre-
vious meta- and pooled analyses remains unclarified
[34,35]. It has to be mentioned that most of the studies
investigating the MTHFR C677T polymorphisms did not
separate rectal and colon cancer patients [35]. Recently,
Cao et al. found that in males, among MTHFR 677TT
genotype carriers, the OR for colon cancer was 2.42, but
that of for rectal cancer was 0.52 [19]. Their result was
similar to ours regarding males older than 60 years with
ORs 1.4 and 0.9 for colon and rectal cancer, respec-
tively. The differing genotype distribution of MTHFR
C677T in Chinese and Caucasian, the different lifestyle,
etc. may account for the more modest difference.
In accordance with the explanations raised by Guer-
reiro et al., - regarding the controversial results of pre-
vious published studies about the CRC risk modified by
the interaction of folate intake and MTHFR 677 poly-
morphism -, we accept the following statement: the low
folate intake and the presence of MTHFR 677T allele or
TT genotype predicts if there is an increased risk of
CRC, while on the contrary high/adequate folate intake
results in a risk reduction if the variant allele is present
[ 1 1 ] .I nH u n g a r yt h ef o l a t ei n t a k ei sg e n e r a l l yl o w[ 3 6 ] ,
thus our result regarding the rectal cancer risk is in
accordance with the previous statement, however, for
colon cancer this relation can be found only in case of
younger individuals (< 60 years). Iacopetta et al. demon-
strated an increased proximal, but not distal CRC risk
in the presence of MTHFR 677T allele and low folate
intake or older (≥ 65 years) individuals. Possible reasons
for the discrepancy between their and our findings
might include the classification of cancers as colon or
rectal and the investigated Australian population con-
sisted not only of Caucasians [37].
In the present study the combination of the SHMT1
1420CT+TT and MTHFR 677CC genotypes was found
to imply the lowest risk for rectal cancer. In a recent
study an interactive influence of MTHFR C677T and
SHMT1 C1420T polymorphisms in the risk of esopha-
geal and gastric carcinomas was also observed [33].
Decreased activity of SHMT1 and the unaltered activity
of MTHFR may result in a decreased amount of 5,10-
MTHF available for pyrimidine synthesis. The combina-
tion with the highest risk is characterized by high
SHMT1 activity and decreased MTHFR activity, which
resulted in an increased availability of folate for pyrimi-
dine synthesis. The impact of the examined
polymorphisms on the DNA methylation is very com-
plex. The decreased activity of SHMT1 may lead to a
decreased DNA methylation through a negative feed-
back chain accumulation of intermediers and decreased
5-methylTHF production.
Our study also suggests the role of gender differences
in the etiology of rectal and colon cancer. Female hor-
mones may influence the susceptibility for second pri-
mary colorectal cancer [38]. Moreover, a statistically
significant association was found between the DNA mis-
match repair gene MSH2 -118T > C polymorphism and
a strong family history of CRC and this association was
seen only in female but not male CRC patients [39].
The age of onset of CRC may also be influenced by
polymorphisms [40]. An age-specific association was
also observed for colon cancer but not for rectal cancer
in case of apolipoprotein E (apoE) polymorphism [41].
The association between BMI and colon cancer
described in a previous large cohort and a pooled study
[16,42] was not demonstarted in our analysis, which
could be due to the insufficient statistical power. The
above studies also demonstrated sex-specific and age-
specific associations.
Gauging the population stratification bias for both
polymorphisms it can be concluded that our findings
are unlikely to be biased. However, it should be consid-
ered that in case of SHMT1 the genotype distributions
and CRC incidence used for calculations were not avail-
able for Hungarian, but only for the European Caucasian
population.
Homocysteine is produced during the methionine
dependent DNA methylation. For its remethylation the
product of the MTHFR enzyme, the 5-methylTHF, is
essential. The less important metabolic transformation
of homocystein implies cystathion beta-synthase or liver
betain-homocysteine methyltransferase. Considering the
important functional role of SHMT1 in the production
of methyl group for multiple metabolic pathways any
disturbance in the protein expression due to the poly-
morphisms could result in the reduction of the available
one-carbon units that is also necessary for the remethy-
lation of homocysteine. Geisel et al. found non-signifi-
cant elevated HCY levels in the SHMT1 1420TT group
in senior healthy subjects [43]. Chen et al. reported sig-
nificantly higher HCY levels in case of SHMT1 1420 CT
genotypes in a study including healthy male subjects
[10]. Similarly, in our study the presence of SHMT 1420
T allele significantly increased the HCY levels in con-
trols. In relative young healthy individuals (20-40 years)
Pereira et al. [21] and Baily et al. [22] found significantly
higher HCY levels in MTHFR 677 TT genotypes com-
pared to the other genotypes. Almost the same result
was found by Semmler et al. [44] with the exception
t h a tt h ea b o v ea s s o c i a t i o nc o u l dn o tb ed e m o n s t r a t e d
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Page 7 of 10for older individuals (> 55 years). This latter data sup-
port our results that in controls (mean age 59 years)
there were no association between HCY levels and
MTHFR 677 polymorphism.
The influence of the investigated polymorphisms on
HCY levels in case of patients may be obscured because
of the much narrow distribution of HCY levels (coeffi-
cient of variation lowered by ~20%) than in controls.
The effect is likely to be in a relationship with a yet
unclarified HCY-increasing mechanism. Proliferating
tumor cells appear to be the main cause of accumula-
tion of HCY and thus, the development of hyperhomo-
cysteinaemia in cancer patients [45]. The tumor marker
character of the HCY, namely the elevated HCY levels
in cancer patients [45-54], the elevated HCY levels in
advanced clinical stages [49,53] and the usefulness of
HCY to monitor therapeutic effects [48,49,54,55] has
also been demonstrated. Moreover, HCY concentration
followed CEA levels in CRC patients [55]. This effect
might be strongly related to the malignant disease pro-
gression as in our study the HCY gradually increased
with the lymph node involvement (Dukes’ stage C) and
further on with the presence of distant metastases
(Dukes’ stage D).
I no u rs t u d yi ts e e m sa taf i r s tg l a n c et h a tH C Yi n
Dukes’ stage C and D is a tumor marker as it was sug-
gested by Wu et al.[ 2 7 ] ,b u ti ft h eSHMT1 1420 poly-
morphism is taken into account then HCY can be
considered as tumor marker only in case of wild (CC)
genotypes. This fact remains valid even for patients of
Dukes’ D stage presenting the highest HCY levels (data
not shown). Similarly, Battistelli et al. presented signifi-
cantly elevated HCY levels compared to controls only in
case of MTHFR 677 CC+CT genotypes [50].
An interesting question would be why the HCY levels
of rectal cancer patients in case of the “lowest rectal
cancer risk"-presenting diplotype are not significantly
higher compared to that of the controls as it can be
seen in case of colon cancers. Could an unknown HCY-
lowering mechanism confer resistance in this context
against rectal carcinogenesis? Based on present results,
it might be supposed, that in case of the risk-reducing
diplotypes the low HCY compared to controls is directly
responsible for reduced risk. On the other hand the low
HCY could be an ancillary result and other mechanisms
may lead to the reduced risk. Recently it was demon-
strated [56] that if the variant SHMT1 is localized in the
nucleus only an impaired de novo thymidylate biosynth-
esis is assured. The thymidylate biosynthesis is further
diminished by the wild-type-MTHFR-transformed and
thus depleted 5,10-MTHF levels. The impaired thymidy-
late biosynthesis is unfavourable for cell proliferation.
These results suggest that the association between the
elevated HCY levels and the cancer risk is not obvious
and first of all the “tumor marker” aspect of HCY needs
to be underlined.
Conclusions
This is the first study presenting the protective effect of
SHMT1 1420T allele or SHMT1 1420 T allele/MTHFR
677 CC diplotype against rectal cancer risk. SHMT1
1420 variant significantly increase HCY levels in con-
trols but not patients. HCY could be considered tumor
marker only in wild-type (CC) SHMT1 1420 CRC
patients in Dukes’ stage C and D. Higher HCY levels are
characteristics of patients in advanced stages of the dis-
ease. Further studies need to be conducted to reveal the
complex role of SHMT1, MTHFR and other folate
enzyme polymorphisms in colon and rectal carcinogen-
esis. The importance of HCY level also need to be
clarified.
Additional material
Additional file 1: Distribution, cancer risk and serum total
homocysteine level of diplotypes. This file contains the distribution,
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CI) level of unpooled SHMT1 1420/MTHFR 677 diplotypes.
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